Pfizer India Managing Director Kewal Handa On Drug Pricing, Patents And Access: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
In one of his final interviews before retirement, Pfizer Managing Director Kewal Handa discusses the Indian government’s policies on drug pricing, compulsory licensing and patents, and foreign direct investments.
You may also be interested in...
Pfizer Vows Disciplined Financial Allocation; Will Not Chase Price For Buyouts In Markets Like India
WASHINGTON - As the socioeconomic shift gains pace and healthcare is given a higher priority by governments, emerging markets like China, Brazil and India have received heightened attention from global companies looking for deal-making opportunities, but lately, unexpected hurdles have cropped up in the way. "Overly exuberant expectations" may be making future alignments hard, say high level seasoned M&A experts
Armed With A Range Of Insulins, Pfizer Is Weeks Away From Its First Biosimilars Rollout In India - BIO 2011 Conference
WASHINGTON - Pfizer Inc. is all set to kick-off its journey into the world of biosimilars as it gives finishing touches to the launch of a range of insulins in India. The company is counting on a set of value propositions, high quality and competitive pricing to emerge as a "natural leader" in the Indian market
China Overlooks Pneumonia Threat; Pfizer Sees Greater Opportunity For Prevenar In India
HONG KONG - Pneumonia is one of China's great killers but it only gets peripheral attention from health authorities, which presents a challenge for companies like Pfizer that are trying to draw interest for vaccines in emerging markets